 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
20 January 2004 | Volume 140 Issue 2 | Pages 85-93
Background: AL amyloidosis is a fatal disease resulting from tissue deposition of amyloid fibrils derived from monoclonal immunoglobulin light chains. Treatment with oral chemotherapy is minimally effective.
Objective: To test survival and organ response in a large sample of patients treated with high-dose intravenous melphalan (100 to 200 mg/m2) and autologous blood stem-cell transplantation.
Design: 8-year longitudinal analysis of clinical effectiveness.
Setting: University-affiliated specialty referral clinic.
Patients: 701 consecutive new patients with AL amyloidosis.
Intervention: High-dose chemotherapy and autologous stem-cell transplantation for patients who met eligibility requirements based on organ involvement and clinical status.
Measurements: Survival analysis of all patients evaluated and a detailed analysis of treatment outcome in the subgroup that received high-dose melphalan and stem-cell transplantation.
Results: Among 701 patients with AL amyloidosis, 394 (56%) were eligible for high-dose melphalan and stem-cell transplantation; 82 did not proceed with treatment because of patient choice or disease progression. Median survival of the 312 patients who initiated treatment was 4.6 years. A complete hematologic response, defined as no evidence of an underlying plasma cell dyscrasia 1 year after treatment, was achieved in 40% of patients and was associated with prolonged survival. Statistically significant improvements occurred in end-organ disease and were greater in patients with a complete hematologic response. Mortality rate within 100 days of treatment with high-dose melphalan and stem-cell transplantation was 13%; patients with cardiomyopathy had the highest mortality rates.
Conclusions: Treatment of selected patients with AL amyloidosis by using high-dose melphalan and stem-cell transplantation resulted in hematologic remission, improved 5-year survival, and reversal of amyloid-related disease in a substantial proportion.
Editors' Notes
Context
Contribution
Implications
–The Editors
Author and Article Information
From Boston University School of Medicine, Boston, Massachusetts.
Acknowledgments: The authors appreciate the contributions of former members of the Amyloid Treatment and Research Program and the Stem Cell Transplant Program who participated in the initial years of this work. They gratefully acknowledge the excellent data management of Arquimedes Areche and Akira Murakami and the patient coordination of Salli Fennessey, Karen Donovan, Serena Baqui, Ceit McCaleb, Lisa Marie Paul, and Julie Cosio. They also thank the many nurses, particularly Rick Kunz, stem-cell transplant nurse coordinator, who participated in the care of these patients.
Grant Support: By grants from the National Institutes of Health (HL 68705), U.S. Food and Drug Administration (FD-R-001346), the Gerry Foundation, the Young Family Amyloid Research Fund, the Sue Sellors Finley Cardiac Amyloid Research Fund, and the Amyloid Research Fund at Boston University. Dr. Seldin is a Scholar of the Leukemia and Lymphoma Society of America.
Potential Financial Conflicts of Interest: None disclosed.
Requests for Single Reprints: Martha Skinner, MD, Amyloid Treatment and Research Program, K503, Boston University School of Medicine, 715 Albany Street, Boston, MA 02118; e-mail, mskinner{at}bu.edu.
Current Author Addresses: Drs. Skinner, Sanchorawala, Seldin, Dember, Falk, Berk, Anderson, O'Hara, Finn, Libbey, Wiesman, Quillen, Swan, and Wright: Amyloid Treatment and Research Program, K503, Boston University School of Medicine, 715 Albany Street, Boston, MA 02118.
Author Contributions: Conception and design: M. Skinner, D.C. Seldin, L.M. Dember, J.L. Berk, C. O'Hara, D.G. Wright,
Analysis and interpretation of the data: M. Skinner, V. Sanchorawala, D.C. Seldin, L.M. Dember, R.H. Falk, J.J. Anderson, D.G. Wright.
Drafting of the article: M. Skinner, V. Sanchorawala, D.C. Seldin, R.H. Falk, D.G. Wright.
Critical revision of the article for important intellectual content: M. Skinner, V. Sanchorawala, D.C. Seldin, L.M. Dember, J.L. Berk, C. O'Hara, J. Wiesman, K. Quillen, D.G. Wright.
Final approval of the article: M. Skinner, V. Sanchorawala, D.C. Seldin, L.M. Dember, R.H. Falk, J.L. Berk, J.J. Anderson, C. O'Hara, K.T. Finn, C.A. Libbey, J. Wiesman, K. Quillen, N. Swan, D.G. Wright.
Provision of study materials or patients: M. Skinner, V. Sanchorawala, D.C. Seldin, R.H. Falk, J.L. Berk, K. Quillen, N. Swan, D.G. Wright.
Statistical expertise: J.J. Anderson.
Obtaining of funding: M. Skinner.
Administrative, technical, or logistic support: M. Skinner, K.T. Finn, K. Quillen, N. Swan, D.G. Wright.
Collection and assembly of data: M. Skinner, C.A. Libbey, J. Wiesman, K. Quillen, N. Swan, D.G. Wright. ARTICLE
High-Dose Melphalan and Autologous Stem-Cell Transplantation in Patients with AL Amyloidosis: An 8-Year Study
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  T. Bochtler, U. Hegenbart, F. W. Cremer, C. Heiss, A. Benner, D. Hose, M. Moos, J. Bila, C. R. Bartram, A. D. Ho, et al. Evaluation of the cytogenetic aberration pattern in amyloid light chain amyloidosis as compared with monoclonal gammopathy of undetermined significance reveals common pathways of karyotypic instability Blood, May 1, 2008; 111(9): 4700 - 4705. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Mignot, F. Bridoux, A. Thierry, S. Varnous, M. Pujo, A. Delcourt, J. M. Gombert, J.-M. Goujon, F. Favreau, G. Touchard, et al. Successful heart transplantation following melphalan plus dexamethasone therapy in systemic AL amyloidosis Haematologica, March 1, 2008; 93(3): e32 - e35. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Bollee, B. Guery, D. Joly, R. Snanoudj, B. Terrier, M. Allouache, L. Mercadal, M.-N. Peraldi, B. Viron, C. Fumeron, et al. Presentation and Outcome of Patients with Systemic Amyloidosis Undergoing Dialysis Clin. J. Am. Soc. Nephrol., March 1, 2008; 3(2): 375 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Bochtler, U. Hegenbart, C. Heiss, A. Benner, F. Cremer, M. Volkmann, J. Ludwig, J. B. Perz, A. D. Ho, H. Goldschmidt, et al. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis Haematologica, March 1, 2008; 93(3): 459 - 462. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F.-U. Sack, A. Kristen, H. Goldschmidt, P. A. Schnabel, T. Dengler, A. Koch, and M. Karck Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis Eur. J. Cardiothorac. Surg., February 1, 2008; 33(2): 257 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Zhou, J. Teruya-Feldstein, P. Lu, M. Fleisher, A. Olshen, and R. L Comenzo Calreticulin expression in the clonal plasma cells of patients with systemic light-chain (AL-) amyloidosis is associated with response to high-dose melphalan Blood, January 15, 2008; 111(2): 549 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kumar, A. Dispenzieri, M. A. Gertz, J. Mehta, H. J. Lachmann, A. D. Wechalekar, J. D. Gillmore, H. M. Lokhorst, B. P.C. Hazenberg, A. Croockewit, et al. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N. Engl. J. Med., January 3, 2008; 358(1): 91 - 92. [Full Text] [PDF]
|
|
|
|
|
|
J. Mehta Amyloidosis: graviores morbos, asperis remedii Blood, November 15, 2007; 110(10): 3490 - 3491. [Full Text] [PDF]
|
|
|
|
|
|
V. Sanchorawala, M. Skinner, K. Quillen, K. T. Finn, G. Doros, and D. C. Seldin Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation Blood, November 15, 2007; 110(10): 3561 - 3563. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Sitia, G. Palladini, and G. Merlini Bortezomib in the treatment of AL amyloidosis: targeted therapy? Haematologica, October 1, 2007; 92(10): 1302 - 1307. [Full Text] [PDF]
|
|
|
|
|
|
E. Kastritis, A. Anagnostopoulos, M. Roussou, S. Toumanidis, C. Pamboukas, M. Migkou, A. Tassidou, I. Xilouri, S. Delibasi, E. Psimenou, et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone Haematologica, October 1, 2007; 92(10): 1351 - 1358. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Gertz, M. Q. Lacy, A. Dispenzieri, S. R. Hayman, S. K. Kumar, N. Leung, and D. A. Gastineau Effect of hematologic response on outcome of patients undergoing transplantation for primary amyloidosis: importance of achieving a complete response Haematologica, October 1, 2007; 92(10): 1415 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jaccard, P. Moreau, V. Leblond, X. Leleu, L. Benboubker, O. Hermine, C. Recher, B. Asli, B. Lioure, B. Royer, et al. High-Dose Melphalan versus Melphalan plus Dexamethasone for AL Amyloidosis N. Engl. J. Med., September 13, 2007; 357(11): 1083 - 1093. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Palladini, P. Russo, M. Nuvolone, F. Lavatelli, V. Perfetti, L. Obici, and G. Merlini Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis Blood, July 15, 2007; 110(2): 787 - 788. [Full Text] [PDF]
|
|
|
|
|
|
D. J. Salant, V. Sanchorawala, and V. D. D'Agati A Case of Atypical Light Chain Deposition Disease--Diagnosis and Treatment Clin. J. Am. Soc. Nephrol., July 1, 2007; 2(4): 858 - 867. [Full Text] [PDF]
|
|
|
|
|
|
L. M. Dember, P. N. Hawkins, B. P.C. Hazenberg, P. D. Gorevic, G. Merlini, I. Butrimiene, A. Livneh, O. Lesnyak, X. Puechal, H. J. Lachmann, et al. Eprodisate for the Treatment of Renal Disease in AA Amyloidosis N. Engl. J. Med., June 7, 2007; 356(23): 2349 - 2360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Leung, A. Dispenzieri, M. Q. Lacy, S. K. Kumar, S. R. Hayman, F. C. Fervenza, S. S. Cha, and M. A. Gertz Severity of Baseline Proteinuria Predicts Renal Response in Immunoglobulin Light Chain-Associated Amyloidosis after Autologous Stem Cell Transplantation Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 440 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. P. Schechter A triple on AL amyloidosis, waiting for a home run Blood, January 15, 2007; 109(2): 391 - 392. [Full Text] [PDF]
|
|
|
|
|
|
V. Sanchorawala, D. G. Wright, M. Rosenzweig, K. T. Finn, S. Fennessey, J. B. Zeldis, M. Skinner, and D. C. Seldin Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial Blood, January 15, 2007; 109(2): 492 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Wechalekar, H. J. B. Goodman, H. J. Lachmann, M. Offer, P. N. Hawkins, and J. D. Gillmore Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis Blood, January 15, 2007; 109(2): 457 - 464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. M. Dember Amyloidosis-Associated Kidney Disease J. Am. Soc. Nephrol., December 1, 2006; 17(12): 3458 - 3471. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Merlini Refining therapy for AL amyloidosis Blood, December 1, 2006; 108(12): 3632 - 3633. [Full Text] [PDF]
|
|
|
|
|
|
D. C. Seldin, J. J. Anderson, M. Skinner, K. Malek, D. G. Wright, K. Quillen, K. Finn, B. Oran, and V. Sanchorawala Successful treatment of AL amyloidosis with high-dose melphalan and autologous stem cell transplantation in patients over age 65 Blood, December 1, 2006; 108(12): 3945 - 3947. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Sanchorawala Light-Chain (AL) Amyloidosis: Diagnosis and Treatment Clin. J. Am. Soc. Nephrol., November 1, 2006; 1(6): 1331 - 1341. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Merlini and M. J. Stone Dangerous small B-cell clones Blood, October 15, 2006; 108(8): 2520 - 2530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. P. Sviggum, M. D. P. Davis, S. V. Rajkumar, and A. Dispenzieri Dermatologic adverse effects of lenalidomide therapy for amyloidosis and multiple myeloma. Arch Dermatol, October 1, 2006; 142(10): 1298 - 1302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Palladini, F. Lavatelli, P. Russo, S. Perlini, V. Perfetti, T. Bosoni, L. Obici, A. R. Bradwell, G. M. D'Eril, R. Fogari, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL Blood, May 15, 2006; 107(10): 3854 - 3858. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Rihova, M. Merta, I. Spicka, J. Zabka, R. Rysava, M. Chochola, E. Meisnerova, I. Vitkova, C. Povysil, J. Reiterova, et al. Unusual manifestation of AL amyloidosis--stenosis of inferior vena cava Nephrol. Dial. Transplant., May 1, 2006; 21(5): 1430 - 1433. [Full Text] [PDF]
|
|
|
|
|
|
R. L. Comenzo, P. Zhou, M. Fleisher, B. Clark, and J. Teruya-Feldstein Seeking confidence in the diagnosis of systemic AL (Ig light-chain) amyloidosis: patients can have both monoclonal gammopathies and hereditary amyloid proteins Blood, May 1, 2006; 107(9): 3489 - 3491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Dispenzieri, M. Q. Lacy, J. A. Katzmann, S. V. Rajkumar, R. S. Abraham, S. R. Hayman, S. K. Kumar, R. Clark, R. A. Kyle, M. R. Litzow, et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation Blood, April 15, 2006; 107(8): 3378 - 3383. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. O. Schonland, H. Lokhorst, A. Buzyn, V. Leblond, U. Hegenbart, G. Bandini, A. Campbell, E. Carreras, A. Ferrant, L. Grommisch, et al. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation Blood, March 15, 2006; 107(6): 2578 - 2584. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Buxbaum Treatment and prevention of the amyloidoses: Can the lessons learned be applied to sporadic inclusion-body myositis? Neurology, January 24, 2006; 66(1_suppl_1): S110 - S113. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Donato, A. M. Feasel, D. M. Weber, V. G. Prieto, S. A. Giralt, R. E. Champlin, and M. Duvic Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation Blood, January 15, 2006; 107(2): 463 - 466. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Leung, T. R. Leung, S. S. Cha, A. Dispenzieri, M. Q. Lacy, and M. A. Gertz Excessive fluid accumulation during stem cell mobilization: a novel prognostic factor of first-year survival after stem cell transplantation in AL amyloidosis patients Blood, November 15, 2005; 106(10): 3353 - 3357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. H. Falk Diagnosis and Management of the Cardiac Amyloidoses Circulation, September 27, 2005; 112(13): 2047 - 2060. [Full Text] [PDF]
|
|
|
|
 |
|
 B. Ng, L. H. Connors, R. Davidoff, M. Skinner, and R. H. Falk Senile Systemic Amyloidosis Presenting With Heart Failure: A Comparison With Light Chain-Associated Amyloidosis Arch Intern Med, June 27, 2005; 165(12): 1425 - 1429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. M. Dember, J.-A. O. Shepard, F. Nesta, and J. R. Stone Case 15-2005 - An 80-Year-Old Man with Shortness of Breath, Edema, and Proteinuria N. Engl. J. Med., May 19, 2005; 352(20): 2111 - 2119. [Full Text] [PDF]
|
|
|
|
|
|
G. Palladini, V. Perfetti, S. Perlini, L. Obici, F. Lavatelli, R. Caccialanza, R. Invernizzi, B. Comotti, and G. Merlini The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL) Blood, April 1, 2005; 105(7): 2949 - 2951. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Komatsuda, N. Maki, H. Wakui, H. Ohtani, T. Hatakeyama, T. Yasuda, Y. Nakamoto, H. Imai, and K.-i. Sawada Development of systemic {lambda}-light chain amyloidosis in a patient with {gamma}-heavy chain deposition disease during long-term follow-up Nephrol. Dial. Transplant., February 1, 2005; 20(2): 434 - 437. [Full Text] [PDF]
|
|
|
|
|
|
D. C. Seldin Interfering with amyloidosis Blood, December 1, 2004; 104(12): 3419 - 3420. [Full Text] [PDF]
|
|
|
|
|
|
M. V. Dhodapkar, M. A. Hussein, E. Rasmussen, A. Solomon, R. A. Larson, J. J. Crowley, and B. Barlogie Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628 Blood, December 1, 2004; 104(12): 3520 - 3526. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jaccard, P. Moreau, V. Leblond, and J.-P. Fermand Best therapy for primary amyloidosis, a not-yet-solved question Blood, November 1, 2004; 104(9): 2990 - 2991. [Full Text] [PDF]
|
|
|
|
|
|
H. J. B. Goodman, P. N. Hawkins, A. Dispenzieri, M. A. Gertz, R. A. Kyle, and J. Mehta The role of PBSCT in treatment of AL amyloidosis is far from settled Blood, November 1, 2004; 104(9): 2991 - 2994. [Full Text] [PDF]
|
|
|
|
|
|
G. Merlini Sharpening therapeutic strategy in AL amyloidosis Blood, September 15, 2004; 104(6): 1593 - 1594. [Full Text] [PDF]
|
|
|
|
|
|
D. C. Seldin, J. J. Anderson, V. Sanchorawala, K. Malek, D. G. Wright, K. Quillen, K. T. Finn, J. L. Berk, L. M. Dember, R. H. Falk, et al. Improvement in quality of life of patients with AL amyloidosis treated with high-dose melphalan and autologous stem cell transplantation Blood, September 15, 2004; 104(6): 1888 - 1893. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mehta High-dose therapy for amyloidosis: the end of the beginning? Blood, May 15, 2004; 103(10): 3612 - 3613. [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Gertz, G. Merlini, and S. P. Treon Amyloidosis and Waldenstrom's Macroglobulinemia Hematology, January 1, 2004; 2004(1): 257 - 282. [Abstract] [Full Text] [PDF]
|
|
Article
